Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.45 |
| ▸ | TYMP | P19971 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095677 | 1.00 | FGFR1 (0.63) | FGFR1SLC22A6HPRT1TYMPSMN1; SMN2 | |
| SCHEMBL1095630 | 0.85 | FGFR1 (0.47) | FGFR1SLC22A6HPRT1TYMPSMN1; SMN2 | |
| SCHEMBL1095637 | 0.80 | FGFR1 (0.47) | FGFR1SLC22A6HPRT1TYMP | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.78 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.78 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.78 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.78 | FGFR1 (1.00) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946566 | 0.77 | SLC22A6 (1.00) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL934593 | 0.77 | FGFR1 (0.98) | FGFR1SLC22A6HPRT1TYMPCYP3A4 | |
| Cidofovir Anhydrous SCHEMBL20770422 | 0.77 | FGFR1 (0.98) | FGFR1SLC22A6HPRT1TYMPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| EP-1966226-B1 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | LEUVEN K U RES & DEV (BE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| EP-1966226-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U.Leuven Research & Development (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | ITPA, ZC3HAV1, MTAP | FGFR1 4874/4885SLC22A6 2692/4885HPRT1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.